Telemedicine and Gestational Diabetes Mellitus: Systematic Review and Meta-Analysis

Omnia S El Seifi1, Faten E Younis1, Yassin Ibrahim1

  • 1Family and Community Medicine, University of Tabuk, Tabuk, SAU.

Cureus
|November 20, 2024
PubMed

Hyperglycemia known as gestational diabetes mellitus (GDM) can happen during pregnancy and poses a risk to the developing baby as well as the mother. Glycemic control, patient involvement, and diabetes management might all be improved via telemedicine (TM). Therefore, this study aimed to compare TM versus standard care for GDM in terms of maternal and fetal outcomes. The authors searched for randomized controlled trials (RCTs) contrasting TM with conventional care among gestational diabetes women across various databases including PubMed, the Cochrane Central Register of Controlled Studies, and Google Scholar from April 2010 to December 2023. This meta-analysis included a total of 2,192 pregnant women from 12 RCT studies and was analyzed by RevMan (version 5.4; Cochrane, London). Applying fixed and random effects was based on heterogeneity. There was a statistically significant difference in the effect on the control of blood glucose levels two-hour postprandial (MD = -0.45, 95%CI = (-0.84, -0.06), P = 0.02) and on the cesarean section effect (RR = 0.74, 95%CI = (0.63, 0.87), P < 0.001) when TM was compared to standard care for GDM. However, there was no statistically significant difference in the effect on other maternal or fetal outcomes such as HBA1c, fasting blood glucose, preterm birth, fetal macrosomia, or hypoglycemia. TM interventions are more successful than standard therapy in lowering the rate of cesarean section and decreasing the two-hour postprandial glucose level of GDM patients, which is essential for improving glycemic control and reducing cardiovascular disease.

Related Concept Videos

Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.2K
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
868
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
236
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.4K
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
174
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
152